|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
GT200500155A
(es)
*
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
|
DK1771482T3
(da)
|
2004-07-22 |
2014-10-20 |
Genentech Inc |
HER2-antistofsammensætning
|
|
JO3000B1
(ar)
*
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
WO2006063042A2
(en)
*
|
2004-12-07 |
2006-06-15 |
Genentech, Inc. |
Selecting patients for therapy with a her inhibitor
|
|
EP1699826B1
(en)
|
2005-01-05 |
2009-03-11 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
|
CN102580084B
(zh)
*
|
2005-01-21 |
2016-11-23 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
|
EP1850874B1
(en)
*
|
2005-02-23 |
2013-10-16 |
Genentech, Inc. |
Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
|
|
MX2007009963A
(es)
|
2005-02-24 |
2007-09-26 |
Amgen Inc |
Mutaciones del receptor del factor de crecimiento epidermico.
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
PL2573114T3
(pl)
*
|
2005-08-10 |
2016-10-31 |
|
Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania
|
|
BRPI0707580A2
(pt)
*
|
2006-02-10 |
2011-05-10 |
Nerviano Medical Sciences Srl |
combinaÇÕes compreendendo um inibidor cdk e um anticorpo do fator de crescimento ou antimitàtico
|
|
EP1999470A4
(en)
*
|
2006-03-10 |
2009-08-19 |
Macrogenics Inc |
IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
|
|
WO2008105886A2
(en)
|
2006-05-26 |
2008-09-04 |
Macrogenics, Inc. |
HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2008002933A2
(en)
*
|
2006-06-26 |
2008-01-03 |
Macrogenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
|
ES2599319T3
(es)
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
EP1878747A1
(en)
|
2006-07-11 |
2008-01-16 |
greenovation Biotech GmbH |
Glyco-engineered antibodies
|
|
WO2008073160A2
(en)
*
|
2006-08-17 |
2008-06-19 |
The Trustees Of Columbia University In The City Of New York |
Methods for converting or inducing protective immunity
|
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
|
US8652466B2
(en)
*
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
SI2132573T1
(sl)
|
2007-03-02 |
2014-07-31 |
Genentech, Inc. |
Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
ES2627223T3
(es)
|
2007-06-26 |
2017-07-27 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Presentación de agentes de unión
|
|
PL2182948T3
(pl)
*
|
2007-07-24 |
2013-07-31 |
Novartis Ag |
Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR
|
|
RU2370280C2
(ru)
*
|
2007-10-08 |
2009-10-20 |
Институт физико-химической биологии им. А.Н.Белозерского |
СПОСОБ СУПЕРПРОДУКЦИИ В РАСТЕНИИ АНТИТЕЛ ПРОТИВ ОНКОГЕНА HER2/neu
|
|
TWI472339B
(zh)
*
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
WO2009123894A2
(en)
*
|
2008-04-02 |
2009-10-08 |
Macrogenics, Inc. |
Her2/neu-specific antibodies and methods of using same
|
|
ES2589912T3
(es)
|
2008-04-02 |
2016-11-17 |
Macrogenics, Inc. |
Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
JP2010006705A
(ja)
*
|
2008-06-13 |
2010-01-14 |
Atlas Antibodies Ab |
Ｈｅｒ２サブセット
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
ES2442024T3
(es)
|
2008-07-15 |
2014-02-07 |
Academia Sinica |
Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
|
|
WO2010051502A2
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
|
AU2010218139B2
(en)
*
|
2009-02-25 |
2012-11-01 |
Merck Sharp & Dohme Corp. |
Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast Pichia pastoris
|
|
WO2010099186A1
(en)
*
|
2009-02-25 |
2010-09-02 |
Merck Sharp & Dohme Corp. |
Her2 antibody compositions
|
|
US8401035B2
(en)
*
|
2009-07-14 |
2013-03-19 |
Level 3 Communications, Llc |
One way SRS information transmission method
|
|
US8064431B2
(en)
*
|
2009-07-14 |
2011-11-22 |
Level 3 Communications, Llc |
One way information transmission method
|
|
US9345661B2
(en)
*
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
CN102770456B
(zh)
|
2009-12-04 |
2018-04-06 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体、抗体类似物、组合物和方法
|
|
EP2513148B1
(en)
*
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anti-her2 antibodies and their uses
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
EP2542256B1
(en)
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
RU2425840C1
(ru)
*
|
2010-04-09 |
2011-08-10 |
Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") |
АНТИТЕЛО, СПЕЦИФИЧЕСКИ ВЗАИМОДЕЙСТВУЮЩЕЕ С ОНКОБЕЛКОМ HER2/neu
|
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
WO2011130580A1
(en)
|
2010-04-15 |
2011-10-20 |
Alper Biotech, Llc |
Monoclonal antibodies against her2 antigens, and uses therefor
|
|
AU2011250970B2
(en)
|
2010-05-10 |
2016-12-15 |
Sinica, Academia |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
|
CA2800769C
(en)
|
2010-05-27 |
2021-11-02 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
|
EP2576621B1
(en)
|
2010-05-27 |
2019-04-10 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
MX347981B
(es)
|
2010-11-01 |
2017-05-22 |
Symphogen As |
Composicion de anticuerpos pan-her.
|
|
WO2012125724A1
(en)
*
|
2011-03-14 |
2012-09-20 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment of proliferative disorders
|
|
AU2012245116A1
(en)
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
|
CA2843158A1
(en)
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
IL301603A
(en)
|
2011-10-14 |
2023-05-01 |
Genentech Inc |
Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
|
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
|
JP6325463B2
(ja)
*
|
2012-03-16 |
2018-05-16 |
コヴァジェン アクチェン ゲゼルシャフト |
抗腫瘍活性を有する新規結合分子
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
NZ700578A
(en)
|
2012-04-17 |
2017-03-31 |
Arsanis Biosciences Gmbh |
Cross-reactive staphylococcus aureus antibody
|
|
ES2431914B2
(es)
*
|
2012-04-27 |
2014-07-24 |
Universidad De Cádiz |
Anticuerpo monoclonal humano ANTI-HER2
|
|
MX2014014162A
(es)
*
|
2012-05-24 |
2015-02-04 |
Hoffmann La Roche |
Anticuerpos multiespecificos.
|
|
WO2013185055A1
(en)
|
2012-06-07 |
2013-12-12 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for the inhibition of pin1
|
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
WO2014015137A2
(en)
*
|
2012-07-18 |
2014-01-23 |
Angion Biomedica Corp. |
Compositions and methods for treating dysproliferative diseases
|
|
BR112015003032B1
(pt)
|
2012-08-13 |
2023-03-28 |
Genentech, Inc |
Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo
|
|
WO2014031498A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
|
AU2013305827A1
(en)
|
2012-08-21 |
2015-03-05 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
|
MX338711B
(es)
|
2012-10-12 |
2016-04-28 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas.
|
|
IL238323B2
(en)
|
2012-10-30 |
2023-11-01 |
Esperance Pharmaceuticals Inc |
Antibody/drug conjugates and methods of use
|
|
EP2738180A1
(en)
*
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
KR102291355B1
(ko)
|
2012-11-30 |
2021-08-19 |
에프. 호프만-라 로슈 아게 |
Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
|
|
WO2014093894A2
(en)
*
|
2012-12-13 |
2014-06-19 |
The Trustees Of The University Of Pennsylvania |
Dna antibody constructs and method of using same
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
HK1220465A1
(zh)
|
2013-03-06 |
2017-05-05 |
Merrimack Pharmaceuticals, Inc. |
抗c-met串联fc双特异性抗体
|
|
MX362970B
(es)
|
2013-03-13 |
2019-02-28 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas.
|
|
CA2908380A1
(en)
|
2013-04-09 |
2014-10-16 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
MX368259B
(es)
*
|
2013-04-16 |
2019-09-25 |
Genentech Inc |
Variantes de pertuzumab y su evaluacion.
|
|
WO2014182970A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
KR101453462B1
(ko)
|
2013-05-16 |
2014-10-23 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
|
EP3013365B1
(en)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2 antigens and use thereof
|
|
EP3013347B1
(en)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
JP6486368B2
(ja)
|
2013-09-06 |
2019-03-20 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
|
|
JP2016538283A
(ja)
|
2013-11-13 |
2016-12-08 |
ザイムワークス，インコーポレイテッド |
Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
|
|
KR101936697B1
(ko)
|
2013-11-19 |
2019-01-10 |
레메젠 리미티드 |
항-her2 항체 및 이의 접합체
|
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
|
EP3083696B1
(en)
|
2013-12-20 |
2018-02-14 |
F.Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
|
AU2014371934B2
(en)
|
2013-12-25 |
2020-01-23 |
Daiichi Sankyo Company, Limited |
Anti-TROP2 antibody-drug conjugate
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
AU2015206370A1
(en)
|
2014-01-16 |
2016-07-07 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
IL310627B2
(en)
*
|
2014-01-31 |
2026-04-01 |
Daiichi Sankyo Co Ltd |
Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
|
|
JP6935195B2
(ja)
|
2014-03-11 |
2021-09-15 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
|
|
ES2809729T3
(es)
|
2014-03-11 |
2021-03-05 |
Molecular Templates Inc |
Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
|
|
KR102399028B1
(ko)
*
|
2014-03-21 |
2022-05-17 |
엑스-바디 인코포레이티드 |
이중-특이적 항원-결합 폴리펩티드
|
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
|
EP3130608B1
(en)
|
2014-04-10 |
2019-09-04 |
Daiichi Sankyo Co., Ltd. |
(anti-her2 antibody)-drug conjugate
|
|
KR20160141857A
(ko)
|
2014-04-25 |
2016-12-09 |
제넨테크, 인크. |
트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
|
|
WO2015164723A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
|
CA2950415A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
|
CN106661099A
(zh)
|
2014-05-27 |
2017-05-10 |
中央研究院 |
抗her2醣抗体及其用途
|
|
JP7093612B2
(ja)
|
2014-05-27 |
2022-06-30 |
アカデミア シニカ |
Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
WO2015184001A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
|
WO2016011265A2
(en)
|
2014-07-17 |
2016-01-21 |
Beth Israel Deaconess Medical Center, Inc. |
Biomarkers for pin1-associated disorders
|
|
WO2016011268A1
(en)
|
2014-07-17 |
2016-01-21 |
Beth Israel Deaconess Medical Center, Inc. |
Atra for modulating pin1 activity and stability
|
|
KR101608301B1
(ko)
|
2014-08-22 |
2016-04-12 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
|
TWI745275B
(zh)
|
2014-09-08 |
2021-11-11 |
中央研究院 |
使用醣脂激活人類ｉＮＫＴ細胞
|
|
EP3193940A1
(en)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
LT3191135T
(lt)
*
|
2014-09-12 |
2020-11-25 |
Genentech, Inc. |
Anti-her2 antikūnai ir imunokonjugatai
|
|
MX2017003472A
(es)
|
2014-09-17 |
2017-10-31 |
Genentech Inc |
Inmunoconjugados que comprenden anticuerpos anti-her2.
|
|
CN104225594B
(zh)
*
|
2014-09-23 |
2016-03-23 |
合肥瀚科迈博生物技术有限公司 |
抗her2人源化抗体及其相关的抗肿瘤组合物
|
|
WO2016082044A1
(en)
|
2014-11-27 |
2016-06-02 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
|
MX2017007187A
(es)
|
2014-12-01 |
2018-01-30 |
Univ Pennsylvania |
Construcciones de anticuerpos de adn y metodo para utilizarlas.
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
JP6779887B2
(ja)
|
2015-01-24 |
2020-11-04 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
新規なグリカンコンジュゲートおよびその使用方法
|
|
CN105985435B
(zh)
*
|
2015-01-30 |
2019-10-15 |
嘉和生物药业有限公司 |
全人源her2抗体的突变抗体及其编码基因和应用
|
|
US10548864B2
(en)
|
2015-03-12 |
2020-02-04 |
Beth Israel Deaconess Medical Center, Inc. |
Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
|
|
WO2016168769A1
(en)
*
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Chimeric receptor t cell switches for her2
|
|
ES3057390T3
(en)
|
2015-05-13 |
2026-03-02 |
Zymeworks Bc Inc |
Antigen-binding constructs targeting her2
|
|
WO2016196373A2
(en)
|
2015-05-30 |
2016-12-08 |
Genentech, Inc. |
Methods of treating her2-positive metastatic breast cancer
|
|
EP3303373B1
(en)
|
2015-05-30 |
2020-04-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
TW201717935A
(zh)
|
2015-06-03 |
2017-06-01 |
波士頓生醫公司 |
用於治療癌症的組成物和方法
|
|
CN116059395A
(zh)
|
2015-06-29 |
2023-05-05 |
第一三共株式会社 |
用于选择性制造抗体-药物缀合物的方法
|
|
KR20180030085A
(ko)
|
2015-07-26 |
2018-03-21 |
몰레큘러 템플레이츠, 인코퍼레이션. |
시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
CN105132357B
(zh)
*
|
2015-07-29 |
2019-12-06 |
苏州诺普再生医学有限公司 |
一种用于表皮细胞培养的无血清培养体系
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
EP3699269A1
(en)
|
2015-09-22 |
2020-08-26 |
F. Hoffmann-La Roche AG |
Expression of fc-containing proteins
|
|
EP3368092B9
(en)
|
2015-10-29 |
2020-07-29 |
Novartis AG |
Antibody conjugates comprising toll-like receptor agonist
|
|
KR20180083874A
(ko)
*
|
2015-11-04 |
2018-07-23 |
사울 제이. 프라이스맨 |
Her2를 표적화하는 키메라 항원 수용체
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
TWI727380B
(zh)
|
2015-11-30 |
2021-05-11 |
美商輝瑞股份有限公司 |
位點專一性ｈｅｒ２抗體藥物共軛體
|
|
EP3426693A4
(en)
|
2016-03-08 |
2019-11-13 |
Academia Sinica |
PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF
|
|
RU2648161C2
(ru)
*
|
2016-04-01 |
2018-03-22 |
Юрий Леонидович Дорохов |
Способ получения антитела, специфически связывающего домен димеризации экзоклеточной части онкобелка HER2/neu, в растении, антитело, полученное этим способом, и его применение
|
|
GEP20227398B
(en)
|
2016-04-15 |
2022-07-25 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
|
|
KR101923624B1
(ko)
|
2016-07-28 |
2018-11-30 |
고려대학교 산학협력단 |
암세포 화학요법을 위한 agtr1 압타머-항암약물 복합체
|
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
|
EP3525829A1
(en)
|
2016-10-11 |
2019-08-21 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
|
WO2018085513A1
(en)
|
2016-11-04 |
2018-05-11 |
Genentech, Inc. |
Treatment of her2-positive breast cancer
|
|
KR101923641B1
(ko)
|
2016-11-25 |
2018-11-29 |
재단법인 목암생명과학연구소 |
항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
|
|
WO2018102427A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
US11273155B2
(en)
|
2016-12-12 |
2022-03-15 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
|
EP3567049A4
(en)
|
2016-12-28 |
2020-08-26 |
Green Cross Lab Cell Corporation |
CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
|
|
EP3562844A1
(en)
|
2016-12-28 |
2019-11-06 |
Genentech, Inc. |
Treatment of advanced her2 expressing cancer
|
|
JP6679762B2
(ja)
|
2017-01-17 |
2020-04-15 |
第一三共株式会社 |
抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート
|
|
TW202508629A
(zh)
|
2017-01-17 |
2025-03-01 |
美商建南德克公司 |
皮下her2抗體調配物
|
|
US11377497B2
(en)
|
2017-01-23 |
2022-07-05 |
Suzhou Alphamab Co., Ltd. |
PD-L1 binding polypeptide or composite
|
|
MX2019008840A
(es)
|
2017-01-25 |
2019-09-09 |
Molecular Templates Inc |
Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
|
|
AU2018219887B2
(en)
|
2017-02-08 |
2024-08-15 |
Dragonfly Therapeutics, LLC |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
CN110944661A
(zh)
*
|
2017-02-20 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
结合her2、nkg2d和cd16的蛋白质
|
|
PT3589661T
(pt)
|
2017-03-02 |
2024-01-29 |
Genentech Inc |
Tratamento com adjuvante de cancro da mama positivo para her2
|
|
WO2018192407A1
(zh)
|
2017-04-19 |
2018-10-25 |
四川科伦博泰生物医药股份有限公司 |
细胞毒素和偶联物、其用途和制备方法
|
|
WO2018200505A1
(en)
|
2017-04-24 |
2018-11-01 |
Genentech, Inc. |
Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
TW202532104A
(zh)
|
2017-05-15 |
2025-08-16 |
日商第一三共股份有限公司 |
抗體－藥物結合物及其用途
|
|
WO2018213424A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
IL324591A
(en)
|
2017-08-31 |
2026-01-01 |
Daiichi Sankyo Co Ltd |
Improved antibody-drug conjugate production methods
|
|
CA3074208C
(en)
|
2017-08-31 |
2023-10-03 |
Daiichi Sankyo Company, Limited |
Novel method for producing antibody-drug conjugate
|
|
JP7710706B2
(ja)
|
2017-09-25 |
2025-07-22 |
シーフイダ ファーマシューティカル グループ （チーリン） カンパニー リミテッド |
癌治療のための方法及び組成物
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
KR102774451B1
(ko)
*
|
2017-11-14 |
2025-02-28 |
앱클론(주) |
항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
|
|
CN119241554A
(zh)
|
2017-12-15 |
2025-01-03 |
四川科伦博泰生物医药股份有限公司 |
生物活性物偶联物及其制备方法和用途
|
|
BR112020015994A2
(pt)
|
2018-02-08 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
|
|
CA3237846A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
WO2019164930A1
(en)
|
2018-02-20 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
EP3773676A4
(en)
*
|
2018-04-03 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
|
|
SG11202007961QA
(en)
|
2018-04-13 |
2020-09-29 |
Hoffmann La Roche |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
|
CN110612117B
(zh)
|
2018-04-17 |
2024-04-12 |
分子模板公司 |
包含去免疫化的志贺毒素a亚基支架的her2靶向分子
|
|
SG11202010496WA
(en)
|
2018-05-18 |
2020-12-30 |
Daiichi Sankyo Co Ltd |
Anti-muc1 antibody-drug conjugate
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US12168691B2
(en)
|
2018-05-31 |
2024-12-17 |
Board Of Regents, The University Of Texas System |
VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof
|
|
WO2020022475A1
(ja)
|
2018-07-27 |
2020-01-30 |
第一三共株式会社 |
抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
|
|
CA3108044A1
(en)
|
2018-07-31 |
2020-02-06 |
Daiichi Sankyo Company, Limited |
Treatment of metastatic brain tumor by administration of antibody-drug conjugate
|
|
MX2021001305A
(es)
|
2018-08-01 |
2021-06-23 |
Cephalon Inc |
Anticuerpos anti-cxcr2 y usos de los mismos.
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
|
|
KR102835308B1
(ko)
|
2018-08-08 |
2025-07-21 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
|
|
EA202190749A1
(ru)
|
2018-09-10 |
2021-07-09 |
Мирати Терапьютикс, Инк. |
Способы комбинированной терапии
|
|
ES2932432T3
(es)
|
2018-10-15 |
2023-01-19 |
Hoffmann La Roche |
Métodos de tratamiento del cáncer de mama residual con trastuzumab emtansina
|
|
WO2020084503A1
(en)
|
2018-10-26 |
2020-04-30 |
Cadila Healthcare Limited |
A composition comprising antibody with reduced level of basic variants thereof
|
|
JP7301155B2
(ja)
|
2019-04-12 |
2023-06-30 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
リポカリンムテインを含む二重特異性抗原結合分子
|
|
EP4058024A1
(en)
|
2019-11-15 |
2022-09-21 |
Seagen Inc. |
Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
|
|
CA3081503A1
(en)
|
2019-12-06 |
2021-06-06 |
Zymeworks Inc. |
Methods of using a bispecific antigen-binding construct targeting her2 in combination with cdk4/6 inhibitors for the treatment of breast cancer
|
|
TWI908779B
(zh)
*
|
2020-03-17 |
2025-12-21 |
美商西雅圖免疫公司 |
引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
|
|
JP7512394B2
(ja)
|
2020-05-06 |
2024-07-08 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
|
|
AU2021295549A1
(en)
|
2020-06-23 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic CD28 antigen binding molecules targeting Her2
|
|
JP2023532122A
(ja)
|
2020-06-29 |
2023-07-26 |
ジェネンテック， インコーポレイテッド |
ペルツズマブにトラスツズマブを加えた固定用量配合剤
|
|
JP2023533813A
(ja)
|
2020-07-14 |
2023-08-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
一定用量配合剤のアッセイ
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
EP4257154A4
(en)
|
2021-02-09 |
2026-04-22 |
Medilink Therapeutics Suzhou Co Ltd |
CONJUGATED WITH A BIOACTIVE SUBSTANCE, ITS PREPARATION PROCESS AND ITS USE
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
AU2022279185A1
(en)
|
2021-05-19 |
2024-01-04 |
Shanghai De Novo Pharmatech Co., Ltd. |
Nitrogen-containing compound, conjugate containing said compound, and application thereof
|
|
US20240307551A1
(en)
|
2021-07-05 |
2024-09-19 |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. |
Antibody-drug conjugate and application thereof
|
|
CA3225975A1
(en)
|
2021-07-22 |
2023-01-26 |
Shanghai Senhui Medicine Co., Ltd. |
Drug conjugate of eribulin derivative
|
|
EP4426727A2
(en)
|
2021-11-03 |
2024-09-11 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
EP4479539A4
(en)
*
|
2022-02-19 |
2026-04-01 |
Salvitus Inc |
PROBIOTIC VACCINES AND ASSOCIATED METHODS OF USE
|
|
WO2024067841A1
(zh)
|
2022-09-30 |
2024-04-04 |
上海迪诺医药科技有限公司 |
苯并氮杂卓衍生物、含其的偶联物及其应用
|
|
TW202434307A
(zh)
|
2023-01-18 |
2024-09-01 |
大陸商泰勵生物科技（上海）有限公司 |
抗體偶聯藥物及其用途
|
|
WO2024173565A2
(en)
*
|
2023-02-14 |
2024-08-22 |
New York University |
Human synthetic antibodies targeting human epidermal growth factor receptor 2 (her2) mutants
|
|
CN121443322A
(zh)
|
2023-07-03 |
2026-01-30 |
施慧达药业集团(吉林)有限公司 |
蛋白质异二聚体的治疗用途
|
|
CN121532829A
(zh)
|
2023-07-14 |
2026-02-13 |
夸登特健康公司 |
使用来自液体活检的dna甲基化对乳腺肿瘤进行分类
|
|
CN120058948B
(zh)
*
|
2023-11-30 |
2025-12-30 |
粤港澳大湾区精准医学研究院(广州) |
一种抗人her2的单克隆抗体及其应用
|
|
WO2025232845A1
(zh)
*
|
2024-05-10 |
2025-11-13 |
四川科伦博泰生物医药股份有限公司 |
具有靶向作用的偶联物及其制备方法和用途
|